{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-029018","form_type":"8-K","ticker":"FEED","cik":"0001326706","company_name":"ENvue Medical, Inc.","filed_at":"2025-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.112606+00:00","generated_at":"2026-05-16T12:13:50.572858+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NanoVibronix amends CEO contract with 9% equity grant; appoints interim CFO","bullets":["CEO Doron Besser new base salary $360K, bonus up to $180K; severance of 12 months' base salary on change-of-control termination.","Besser receives 180,000 RSUs (9% of outstanding common stock) plus annual grants to maintain 9% equity.","CFO Stephen Brown departed Dec. 18, 2025; Nicole Fernandez-McGovern appointed Interim CFO via consulting agreement with RCM Financial Consulting.","Fernandez-McGovern receives $300K annual salary; served as CFO of NLS Pharmaceutics and interim CFO of Hayden AI."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-029018","json":"https://secwatch.observer/filing/0001493152-25-029018.json","markdown":"https://secwatch.observer/filing/0001493152-25-029018.md","text":"https://secwatch.observer/filing/0001493152-25-029018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326706/000149315225029018/0001493152-25-029018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326706/000149315225029018/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:13:50.572858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}